BridgeMD
New treatment option for Ventricular Tachycardia
Official title Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
ClinicalTrials.gov ID: NCT06281977
What this study is testing
What is Dexmedetomidine?
Dexmedetomidine is an investigational medicine, being studied as a potential treatment for ventricular tachycardia.
Also referred to as Precedex.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- \- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.
You likely can't join if
- Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors
- SCAI class D or E cardiogenic shock
- Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.
- ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.
- Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater...
- Pregnancy
See the full eligibility criteria
- \- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.
- Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors
- SCAI class D or E cardiogenic shock
- Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.
- ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.
- Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.
- Pregnancy
- Known dexmedetomidine allergy or intolerance
- Inability to obtain consent from patient or substitute decision maker.
- Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization
The study team makes the final eligibility decision.
Where it's taking place
- Rochester, Minnesota, United States
- Ottawa, Ontario, Canada
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rochester, Minnesota, United States; Ottawa, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.